Eli Lilly10-Q: Quality issueAug 5, 2026

Actively fighting counterfeit versions of its blockbuster incretin drugs.

What happened

The company is battling the production and sale of counterfeit, misbranded, and adulterated versions of its key drugs, creating a critical need for solutions in brand protection, supply chain traceability, and anti-counterfeiting technology to safeguard patients and revenue.

Source

SEC EDGARAug 5, 2026

Quarterly report (Form 10-Q)

Eli Lilly 10-Q

Filing excerpt

We continue to see the production, marketing, and sale of counterfeit, misbranded, adulterated, and mass-compounded incretins.

sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htmRead the full source

Other signals in this filing (11)

Acquisition completedEli Lilly spends $13.3B on five strategic acquisitions in 2026 to expand its pipeline.Acquisition completedAug 5, 2026
Acquisition announcedEli Lilly announces pending acquisition of AtaiBeckley Inc. for approximately $2.8 billion.Acquisition announcedAug 5, 2026
RestructuringSpent over $15B on acquisitions in 2026, driving major integration costs and restructuring.RestructuringAug 5, 2026
Capex increaseLilly announces "meaningfully higher" capital expenditures for global manufacturing expansion.Capex increaseAug 5, 2026
Debt refinancingRaised $9.0 billion in long-term debt in May 2026 to fund M&A and corporate purposes.Debt refinancingAug 5, 2026
Capacity constraintSignificantly increasing capital expenditures for global manufacturing facility expansion.Capacity constraintAug 5, 2026
Inflation impactLower realized prices for Mounjaro & Zepbound offset strong volume growth, especially in China.Inflation impactAug 5, 2026
Restructuring chargeIncurred $703M in restructuring and M&A integration charges in Q2 2026.Restructuring chargeAug 5, 2026
Pricing pressureFacing pricing pressure on key drugs Mounjaro and Zepbound in the U.S. and China.Pricing pressureAug 5, 2026
Product launchMarketing and sales spend increases 25% to support ongoing and planned product launches.Product launchAug 5, 2026
Litigation materialActively filing lawsuits to combat counterfeit versions of its incretin drugs.Litigation materialAug 5, 2026

Extracted by Autobound

From the Signal API record

Signal: 10-Q: Quality issue

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end: 06/30
Filed: Aug 5, 2026

More 10-Q signals at other companies

SEC 10-QMillerKnoll, Inc.Jeffrey M. Stutz appointed Interim Chief Executive Officer.SEC 10-QSep 28, 2026
SEC 10-QCID HoldCo, Inc.Disclosed material weaknesses in financial reporting due to insufficient accounting staff and controls.SEC 10-QSep 25, 2026
SEC 10-QScholastic CorporationCore school channels decline with fewer book fairs and lower club participation.SEC 10-QSep 25, 2026

The full record

From the Signal API record

Details

CIK: 59478
Accession number: 0000059478-26-000081
Timeframe: Current quarter
Filing year: 2026
Fiscal year: 0
Why it matters: Quality management needed
Signal category: Operations

Extraction

Confidence: High
Relevance: 90%
Sentiment: Negative
Detected: Aug 11, 2026
signal_type: sec-10q
signal_subtype: qualityIssue

Use this data

Get every 10-Q signal for Eli Lilly and the companies you sell to, in the tools you already use.

Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Eli Lilly this week?”
MCP setup guide
Send it to your own tools
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Signal API
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

linkedin_urlValue in the API
industriesValue in the API
employee_count_lowValue in the API
employee_count_highValue in the API
revenueValue in the API
descriptionValue in the API

Signal

signal_nameValue in the API
associationValue in the API

Start Free1,000 free creditsUse it in Claude via MCP

Show the full JSONThe record on this page and the API request

GET /v1/signals/1279bf6b-e9ab-42eb-a36c-53f13956bd62 returns this record as JSON. POST /v1/companies/enrich returns every signal for lilly.com.

{
  "signal_id": "1279bf6b-e9ab-42eb-a36c-53f13956bd62",
  "signal_type": "sec-10q",
  "signal_subtype": "qualityIssue",
  "detected_at": "2026-08-11T08:09:31.99+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "detail": "The company is battling the production and sale of counterfeit, misbranded, and adulterated versions of its key drugs, creating a critical need for solutions in brand protection, supply chain traceability, and anti-counterfeiting technology to safeguard patients and revenue.",
    "metrics": {
      "timeframe": "current_quarter"
    },
    "summary": "Actively fighting counterfeit versions of its blockbuster incretin drugs.",
    "excerpts": "We continue to see the production, marketing, and sale of counterfeit, misbranded, adulterated, and mass-compounded incretins.",
    "relevance": 0.9,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm",
    "filing_date": "2026-08-05",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "06/30",
    "sales_relevance": "Quality management needed",
    "signal_category": "operations"
  }
}

curl https://signals.autobound.ai/v1/signals/1279bf6b-e9ab-42eb-a36c-53f13956bd62 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"lilly.com","limit":20}'

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.